The co-incubation programme is a joint collaboration between HKSTP, Shanghai Pharmaceuticals (SPH), and its subsidiary, Biopharma Evolution. The programme helps to fast-track novel life science innovations (with focus on autoimmune diseases, anti-ageing, gene and cell therapy, mRNA/siRNA, and other areas of novel breakthrough potential) to the Greater Bay Area (GBA), and the Yangtze River Delta (YRD) led by Shanghai. Leveraging SPH's extensive network of resource and experience, the programme offers up to seven years of sponsorships/partnering with in-depth support on full spectrum R&D resources, commercialisation, and capital investment opportunities including connections to Contract Research Organisations (CRO) and Contract Development and Manufacturing Organisations (CDMO) across Mainland and Asia Pacific Regions.